Munteanu Madalina Andreea, Nicolae Camelia, Popescu Razvan Ionut, Rusescu Andreea, Paun Nicolae, Nanea Tiberiu Ioan
Internal Medicine and Cardiology Department, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Cardiology and Urology Department, Clinical Hospital "Prof. Dr. Th. Burghele", 050659 Bucharest, Romania.
Biomedicines. 2025 Feb 6;13(2):389. doi: 10.3390/biomedicines13020389.
Renal abscess represents one infectious urological complication with lethal potential. The treatment of this pathology may differ depending on the severity of the symptoms and the size of the infectious collection. Diabetes, immunosuppression, and associated urinary pathologies are most frequently responsible for the development of abscesses. This case report presents the first documented case of a renal abscess associated with Sodium-glucose cotransporter 2 (SGLT2) inhibitors in a person without previous predisposing pathologies. A 62-year-old patient presented to the emergency department for pain in the right flank, vomiting, and dysuria. The patient's medical history revealed Heart Failure New York Heart Association (NYHA) Class II, Coronary Artery Disease (CAD) with prior angioplasty, and permanent Atrial Fibrillation. No prior urological or immunosuppressive conditions were detected. The Computed Tomography (CT) evaluation confirmed the ultrasound suspicion of a right renal abscess performed in the emergency room. The only risk factor identified was the initiation of SGLT2 inhibitor therapy for cardiac pathology approximately 2 months before. According to the small dimensions and urine culture, the abscess was successfully treated with antibiotic administration in collaboration with the urology department. The infectious process was remitted within 2 weeks. To our knowledge this is the first documented case of a renal abscess associated with SGLT2 inhibitor administration in a person without previous predisposing risk factors. Despite the relatively low incidence of urinary tract infections (UTIs) associated with SGLT2 inhibitors, their widespread use in the treatment of various socially significant conditions highlights the need for both patients and medical specialists to be aware of all potential risks and pay increased attention to these cases.
肾脓肿是一种具有致命潜在风险的感染性泌尿系统并发症。这种病症的治疗方法可能因症状的严重程度和感染灶的大小而有所不同。糖尿病、免疫抑制以及相关的泌尿系统疾病是脓肿形成的最常见原因。本病例报告展示了首例记录在案的、在无先前易患疾病的患者中发生的与钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂相关的肾脓肿病例。一名62岁的患者因右侧胁腹疼痛、呕吐和排尿困难前往急诊科就诊。患者的病史显示有纽约心脏协会（NYHA）II级心力衰竭、既往接受过血管成形术的冠状动脉疾病（CAD）以及永久性心房颤动。未检测到先前的泌尿系统或免疫抑制情况。计算机断层扫描（CT）评估证实了急诊室超声检查怀疑的右肾脓肿。唯一确定的风险因素是大约2个月前因心脏疾病开始使用SGLT2抑制剂治疗。根据脓肿尺寸较小以及尿液培养结果，通过与泌尿外科合作给予抗生素治疗，脓肿得到了成功治疗。感染过程在2周内得到缓解。据我们所知，这是首例记录在案的、在无先前易患风险因素的患者中发生的与SGLT2抑制剂使用相关的肾脓肿病例。尽管与SGLT2抑制剂相关的尿路感染（UTIs）发生率相对较低，但它们在治疗各种具有社会重要性的病症中的广泛应用凸显了患者和医学专家都需要了解所有潜在风险并更加关注这些病例。
